Nonalcoholic fatty liver disease (NAFLD) embraces histopathological entities ranging from the relatively
benign simple steatosis to the progressive form nonalcoholic steatohepatitis (NASH), which is associated
with fibrosis and an increased risk of progression to cirrhosis and hepatocellular carcinoma. NAFLD is the most
common liver disease and is associated with extrahepatic comorbidities including a major cardiovascular disease
The non-invasive diagnosis of NAFLD and the identification of subjects at risk of progressive liver disease and
cardio-metabolic complications are key in implementing personalized treatment schedules and follow-up strategies.
In this review, we highlight the potential role of ultrasound semiquantitative scores for detecting and assessing
steatosis severity, progression of NAFLD, and cardio-metabolic risk.
Ultrasonographic scores of fatty liver severity act as sensors of cardio-metabolic health and may assist in selecting
patients to submit to second-line non-invasive imaging techniques and/or liver biopsy.